Tom Plitz (L) and Arthur Roach, Chord Therapeutics CEO and founder

Mer­ck KGaA snatch­es up Gene­va biotech as re­pur­posed chemother­a­py mis­sion strikes a 'Chord'

About a year af­ter Gene­va-based Chord Ther­a­peu­tics emerged from stealth to see if it could re­pur­pose an old chemother­a­py agent for rare dis­eases, Mer­ck KGaA is swoop­ing in with a buy­out.

While the com­pa­nies are keep­ing mum about the fi­nan­cial terms of the deal, Mer­ck KGaA is adding Chord’s lead can­di­date to its neu­rol­o­gy pipeline — a small mol­e­cule oral ver­sion of the chemother­a­py drug cladrib­ine dubbed CRD1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.